Compare Adaptive Biotechnologies Corp (ADPT) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Futu Holdings Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.23 (market cap $3.33B), while Futu Holdings Ltd trades at $95.8 (market cap $13.19B). The key difference: Futu Holdings Ltd is far larger — about 4× Adaptive Biotechnologies Corp's market cap, and Futu Holdings Ltd pays a 2.76% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FUTU | |
|---|---|---|
Market Cap | $3.33B | $13.19B |
Sector | Health | Financials |
52-Week High | $22.37 | $199.04 |
52-Week Low | $10.24 | $89.76 |
Enterprise Value | $3.19B | $13.04B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
FUTU trades at $94.03, down 1.06% on the day, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $22.85B in 2025 and a net income margin of 41.83%, but faces multiple securities class action lawsuits alleging fraud related to undisclosed regulatory penalties. Valuation ratios appear attractive with a P/E of 10.85 and EV/EBITDA of 7.16.
The outlook is clouded by legal risks and mixed earnings performance, with recent misses on EPS estimates. Analyst consensus remains positive with 58% buy ratings, but investors must weigh solid fundamentals against significant litigation overhangs and regulatory scrutiny that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
